Lefmaa 20 Tablet contains Leflunomide 20 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide exerts its therapeutic effect by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This immunomodulatory action helps to alleviate symptoms such as joint pain, swelling, and stiffness, and may slow the progression of structural joint damage. Lefmaa 20 is typically prescribed as part of a comprehensive treatment plan and may be used alone or in combination with other disease-modifying agents. Patients should be monitored regularly for liver function, blood cell counts, and signs of infection due to potential adverse effects including hepatotoxicity, immunosuppression, and gastrointestinal disturbances. Leflunomide is contraindicated in pregnancy due to teratogenicity and requires effective contraception during treatment and for an extended period after discontinuation. Dose adjustments may be necessary in patients with hepatic impairment. Lefmaa 20 Tablet should be administered under medical supervision with adherence to recommended guidelines to optimize therapeutic outcomes and minimize risks.